Navigation Links
Ariosa Diagnostics Wins Summary Judgment Against Sequenom on Cell-free DNA Patent
Date:10/31/2013

SAN JOSE, Calif., Oct. 31, 2013 /PRNewswire/ -- Ariosa Diagnostics, Inc., won summary judgment yesterday in a patent infringement litigation involving U.S. Patent No. 6,258,540 against Sequenom, Inc., an exclusive licensee of the patent from Isis Innovations, Inc.  The United States District Court for the Northern District of California invalidated the '540 patent at issue, giving Ariosa a complete victory in the case. The patent at issue is related to the detection of fetal cell-free DNA in the bloodstream of pregnant women, and Sequenom claimed that it applied to tests for the determination of certain fetal genetic characteristics. The Court invalidated Sequenom's patent because it attempts to cover this natural phenomenon, which the Court found is not patent-eligible subject matter.

(Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO)

"Ariosa is an innovator in prenatal testing, and we are extremely pleased with the Court's decision in our favor," said Dianna DeVore, vice president of intellectual property and legal affairs at Ariosa Diagnostics. The ruling extends established Supreme Court and Federal Circuit precedent, and validates Ariosa's long-standing view that it has freedom to develop new, innovative and market-leading technologies to provide improved genetic testing for pregnant women.

In light of repeated public threats by Sequenom regarding enforcement of its '540 patent, Ariosa filed suit against Sequenom in December 2011, seeking a declaratory judgment that its Harmony™ Prenatal Test did not infringe Sequenom's patent. Sequenom counterclaimed for patent infringement and moved for a preliminary injunction.

Sequenom unsuccessfully spent almost two years trying to prevent Ariosa from making and selling the Harmony Prenatal Test, a proprietary and innovative test that provides important information about whether a fetus is at risk of having certain chromosomal abnormalities, including Down syndrome, based on a simple blood draw from a pregnant woman.

Ariosa is represented in the litigation by Irell & Manella LLP.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony™ Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony™ Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT:
Jen Bruursema
408-229-7539
jbruursema@ariosadx.com


'/>"/>
SOURCE Ariosa Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
2. Ariosa Diagnostics Introduces Y-Chromosome Analysis Test Option
3. QBC Diagnostics Awarded GSA Contract
4. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
5. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
6. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
7. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
8. Breakthrough Prostate Cancer Diagnostics
9. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
10. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
11. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... of its Pflugerville- FM 685 facility. , “We are pleased to announce Dr. ... said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room – ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... When it ... Parents and guardians deserve clear instructions on how to keep babies and toddlers safe, ... which is Baby Safety Month. , Great Time to Check Labels, Brands that sell ...
(Date:9/19/2017)... ... 19, 2017 , ... With Netmail Hadron, construction ... United States, can easily manage all of their data, apply policies on that ... simultaneously. “As a construction company,” says Ryan Sinnwell, the Infrastructure Manager at The ...
(Date:9/18/2017)... ... September 18, 2017 , ... A September 7 article ... that aspirin, one of the world’s most common and least expensive medications, may be ... dentist Dr. Farzad Feiz of California Dental Group and Calabasas Dental Care says that, ...
(Date:9/18/2017)... ... , ... Allegheny Health Network’s (AHN) string of standout showings at the Pittsburgh ... earned more honors than any health care provider in the region at the annual ... the Omni William Penn Hotel in downtown Pittsburgh included:, , ...
Breaking Medicine News(10 mins):